Novanta Inc. (NOVT) SEC Filings & Earnings Calls
EquiReason read 16 Novanta Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — Novanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medi.
Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason
- Market cap
- 5.3B
- P/E TTM
- 89.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Aug 202610-QNovanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medical.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $266M | +10% y/y |
| Gross Profit Margin - Automation Enabling Technologies · Automation Enabling Technologies · Q2-2026 | 52.6% | |
| Gross Profit Margin - Medical Solutions · Medical Solutions · Q2-2026 | 38.8% | |
| Operating Income · Q2-2026 | $18M | +21% y/y |
| Net Cash Provided by Operating Activities · H1-2026 | $117M | |
| Cash and Cash Equivalents · 2026-07-03 | $719M | |
| Diluted Earnings Per Share · Q2-2026 | $0.30 |
Risks flagged
Tariff cost pressure
“Tariffs imposed by the U.S. government on imports from certain countries, including China, continue to put pressure on our cost to serve customers.” · word for word
Geopolitical supply chain disruption
“The conflict arising from coordinated US and Israeli military strikes on Iran beginning in February 2026, and Iran's subsequent retaliatory actions, including the temporary closure of the Strait of Hormuz, has contributed to increased global energy prices, heightened supply chain uncertainty, and rising freight and commodity costs.” · word for word
Integration risk from large acquisition
“On July 23, 2026, we completed the acquisition of all outstanding equity interests of the parent company of Riverpoint Medical for total upfront cash consideration of $1.2 billion.” · word for word
Medical Solutions margin pressure
“Medical Solutions segment gross profit margin was 38.8% for the three months ended July 3, 2026, versus a gross profit margin of 41.5% for the prior year period. The decrease in gross profit margin was primarily due to changes in product mix and temporary cost increases incurred as part of our operational transformation.” · word for word
5 Aug 20268-K · 2.02Q2 2026 revenue $266M (+10% YoY), adjusted EBITDA $61M (+16%), both above expectations; guidance raised for Q3 and FY2026; Riverpoint Medical acquisition closed.open
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $266M | +10% y/y |
| Operating Income · Q2-2026 | $18M | +21% y/y |
| Net Income · Q2-2026 | $13M | +178% y/y |
| Diluted EPS · Q2-2026 | $0.30 | +150% y/y |
| Adjusted Operating Income · Q2-2026 | $48M | +17% y/y |
| Adjusted Diluted EPS · Q2-2026 | $0.89 | +17% y/y |
| Adjusted EBITDA · Q2-2026 | $61M | +16% y/y |
| Operating cash flow · Q2-2026 | $65M | +330% y/y |
| Year-to-date operating cash flow · H1-2026 | $117M | +149% y/y |
| Adjusted Gross Margin · Q2-2026 | 47.0% |
Guidance
Q3 2026 revenue $300-304M (>21% growth); adjusted EBITDA $74-77M; adjusted diluted EPS $0.95-1.00. FY2026 revenue $1,130-1,140M (>15% growth); adjusted EBITDA $273-278M (>24% growth); adjusted diluted EPS $3.68-3.74 (>12% growth).
Guidance raised for Q3 and FY2026, incorporating Riverpoint Medical acquisition; strong momentum across portfolio
Risks flagged
Integration risk from Riverpoint Medical acquisition
“Acquisition integration risk; financial projections not subject to same accounting oversight”
Foreign exchange exposure
“Guidance assumes no significant changes in foreign exchange rates; FX favorably impacted revenue by $2.4M”
Tariff and trade policy risk
“Exposure to increased tariffs, trade restrictions or taxes on products”
27 Jul 20268-K · 2.01, 2.03, 7.01Closing Consideration $1.20B; Milestone Payment $250M; Borrowings under Credit Agreement $616Macquisitionopen
Figures in the filing · each found in the filing text
| Closing Consideration · Q2-2026 | $1.20B | |
| Milestone Payment · Q2-2026 | $250M | |
| Borrowings under Credit Agreement · Q2-2026 | $616M | |
| Consolidated Debt · Q2-2026 | $855M |
Risks flagged
Increased leverage from debt-financed acquisition.
“Debt increased to $854.7M from $616M borrowing.”
9 Jun 20268-K · 1.01, 3.02, 8.01Novanta Inc. filed an 8-K regarding a private placement of unregistered shares, indicating equity dilution. The filing includes a Securities Purchase Agreement and Registration Rights Agreement, but no specific dollar amount or share countopen
Risks flagged
Dilution of existing shareholders by ~5.7%.
“Based on 35,613,303 Common Shares outstanding... and an additional 4,717,185 Common Shares... there would be an aggregate of 42,473,345 Common Shares outstanding... following the Closing.”
9 Jun 20268-K · 1.01, 7.01Novanta announces acquisition of Riverpoint Medical for $1.2B upfront plus $250M milestone, expanding into minimally invasive surgery consumables, doubling recurring medical consumables revenue to ~$300M, immediately accretive to margins anacquisitionopen
Risks flagged
Increased leverage from financing acquisition with credit facilities and equity issuance.
“The Transaction will be financed through a combination of cash on hand, the Company’s existing credit facilities... and proceeds from the Company’s equity issuance announced today.”
15 May 20268-K · 1.01, 2.03Novanta entered into a Second Amendment to its credit agreement, establishing $200M delayed draw term loan commitments maturing June 2030, with interest based on leverage ratio.open
Risks flagged
Increased debt capacity may lead to higher leverage if drawn.
“The Delayed Draw Term Loans will mature on June 27, 2030 and shall bear interest... plus a margin.”
11 May 202610-QTotal Revenue $258M (+10% y/y); Automation Enabling Technologies Revenue $131M (+7% y/y); Medical Solutions Revenue $126M (+15% y/y)open
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $258M | +10% y/y |
| Automation Enabling Technologies Revenue · Automation Enabling Technologies · Q1-2026 | $131M | +7% y/y |
| Medical Solutions Revenue · Medical Solutions · Q1-2026 | $126M | +15% y/y |
| Gross Profit Margin · Q1-2026 | 44.1% | |
| Operating Income · Q1-2026 | $28M | -15% y/y |
| Operating Cash Flow · Q1-2026 | $52M | +63% y/y |
| Diluted EPS · Q1-2026 | $0.51 | -14% y/y |
Risks flagged
Tariff-driven margin compression
“Tariffs imposed by the U.S. government on imports from certain countries, including China, have increased our cost of revenue and contributed to gross margin compression in both of our reportable segments during the three months ended April 3, 2026.” · word for word
Geopolitical conflict supply chain risk
“the conflict arising from coordinated US and Israeli military strikes on Iran beginning in February 2026, and Iran's subsequent retaliatory actions, including the temporary closure of the Strait of Hormuz, has contributed to increased global energy prices, heightened supply chain uncertainty, and rising freight and commodity costs.” · word for word
11 May 20268-K · 2.02Novanta Q1 2026 revenue $257.7M (+10.4% YoY), bookings +37% YoY, book-to-bill 1.10, Adj. EBITDA +14.2% to $57.1M, Adj. EPS +9.5% to $0.81. Raised Q2 organic growth guidance to 6-8%.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $258M | +10% y/y |
| Adjusted EBITDA · Q1-2026 | $57M | +14% y/y |
| Adjusted Diluted EPS · Q1-2026 | $0.81 | +9% y/y |
| GAAP Diluted EPS · Q1-2026 | $0.51 | -14% y/y |
| Net Income · Q1-2026 | $21M | -0% y/y |
| Operating Cash Flow · Q1-2026 | $52M | +63% y/y |
| Organic Revenue Growth · Q1-2026 | 3.1% | |
| Bookings Growth · Q1-2026 | 37.0% | |
| Book-to-Bill Ratio · Q1-2026 | $1.10 |
Guidance
Q2 2026 GAAP revenue $259-264M; Adj. EBITDA $58-62M; Adj. EPS $0.81-0.86. FY26 GAAP revenue $1,040-1,055M; Adj. EBITDA $245-250M; Adj. EPS $3.50-3.65. Q2 organic growth 6-8% (vs Q1 organic 3.1%).
Raised Q2 organic growth guidance to 6-8% from Q1's 3.1% actual, supported by strong bookings and backlog. Full-year guidance implies continued momentum.
Risks flagged
Trade and economic climate uncertainty could impact demand
“rigorously executing in a dynamic trade and economic climate” · word for word
GAAP operating income declined due to acquisition-related costs
“GAAP operating income was $27.5 million, compared to $32.4 million in the prior year” · word for word
24 Apr 2026DEF 14AAnnual proxy statement disclosing executive compensation, governance, and 2025 financial results.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $981M | +3% y/y |
| Net Income · FY2025 | $54M | -16% y/y |
| Adjusted EBITDA · FY2025 | $221M | +5% y/y |
| Operating Cash Flow · FY2025 | $64M | -60% y/y |
| Organic Revenue Growth · FY2025 | -0.5% |
Risks flagged
Operating cash flow decline
“Operating cash flow was $64.1 million for fiscal year 2025, a decrease of $94.4 million from $158.5 million for fiscal year 2024.” · word for word
Negative organic revenue growth
“Organic Revenue Growth was (0.5)% for the fiscal year 2025.” · word for word
Underperformance vs. peers
“Total Shareholder Return Year Ended December 31, 2025 Novanta Inc. -22 % Russell 2000 Index 13 %” · word for word
23 Feb 202610-KRevenue $981M (+3% y/y); Automation Enabling Technologies Revenue $501M (+2% y/y); Medical Solutions Revenue $480M (+5% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $981M | +3% y/y |
| Automation Enabling Technologies Revenue · Automation Enabling Technologies · FY2025 | $501M | +2% y/y |
| Medical Solutions Revenue · Medical Solutions · FY2025 | $480M | +5% y/y |
| Gross Profit Margin · FY2025 | 44.4% | |
| Net Income · FY2025 | $54M | -16% y/y |
| Total Debt · 2025-12-31 | $260M | |
| R&D Expense · FY2025 | $95M | 0% y/y |
| SG&A Expense · FY2025 | $196M | +11% y/y |
Risks flagged
Customer Concentration
“Our top ten customers accounted for approximately 42% of our sales for the year ended December 31, 2025.” · word for word
Foreign Exchange Exposure
“In the event of a decline in the value of the Euro, British Pounds, Chinese Yuan or Japanese Yen, we typically experience a decline in our revenues and profit margins.” · word for word
Intangible Asset Impairment Risk
“As of December 31, 2025, we had $828.1 million of net intangible assets, including goodwill, on our consolidated balance sheet.” · word for word
23 Feb 20268-K · 2.02Revenue $258M (+8% y/y); Adjusted Diluted EPS $0.91 (+20% y/y); Adjusted EBITDA $61M (+17% y/y); Guidance: FY2026 revenue guidance $1.03-1.05B vs FY2025 $981M; Adj. EBITDA $245-250M vs $221M; Adj. EPS $3.50-3.65 vs $3.29earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $258M | +9% y/y |
| Adjusted Diluted EPS · Q4-2025 | $0.91 | +20% y/y |
| Adjusted EBITDA · Q4-2025 | $61M | +17% y/y |
| GAAP Diluted EPS · Q4-2025 | $0.45 | -2% y/y |
| Operating Cash Flow · Q4-2025 | $9M | -86% y/y |
| Bookings Growth · Q4-2025 | 25.0% | |
| Book-to-Bill · Q4-2025 | $1.11 | |
| Total Debt · FY2025 | $251M |
Guidance
FY2026 revenue guidance $1.03-1.05B vs FY2025 $981M; Adj. EBITDA $245-250M vs $221M; Adj. EPS $3.50-3.65 vs $3.29
Management raised FY2026 guidance across all key metrics, citing strong bookings, new product momentum, and margin improvement from operational initiatives.
Risks flagged
Temporary operating cash flow pressure from regionalization strategy
“Operating cash flow was $8.8 million, compared to $61.6 million in the prior year. The year-over-year decrease in operating cash flow was primarily driven by the Company’s strategy to regionalize manufacturing, which resulted in temporary increases in net working capital.” · word for word
Trade cost and disruption exposure
“regionalize manufacturing to mitigate the effects of trade costs and disruptions on our customers when purchasing Novanta’s products” · word for word
13 Nov 20258-K · 7.01Novanta revised Q4 and FY2025 adjusted diluted EPS guidance downward to reflect equity issuance dilution; revenue and EBITDA guidance unchanged.open
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $253M | |
| Revenue · FY2025 | $975M | |
| Adjusted EBITDA · Q4-2025 | $62M | |
| Adjusted EBITDA · FY2025 | $222M | |
| Adjusted Diluted EPS · Q4-2025 | $0.84 | -3% y/y |
| Adjusted Diluted EPS · FY2025 | $3.21 | -1% y/y |
Guidance
Q4 2025 Adjusted Diluted EPS revised to $0.84-$0.91 from $0.87-$0.93; FY2025 revised to $3.21-$3.28 from $3.24-$3.30. Revenue and EBITDA guidance unchanged.
EPS guidance cut due to share dilution from equity issuance; operational guidance unchanged.
Risks flagged
EPS dilution from equity issuance; no change to revenue or EBITDA guidance.
“Guidance revision reflects share count increase from equity issuance, not operational deterioration.”
12 Nov 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen
Risks flagged
Dilution risk from equity offering
“Tangible equity units offering may dilute existing shareholders if converted to equity.”
Debt obligation increase
“Item 2.03 indicates creation of a direct financial obligation.”
3 Nov 20258-K · 2.02Revenue $248M (+1% y/y); GAAP Net Income $11M; Adjusted EBITDA $58M; Guidance: Q4 revenue $253M-$257M; FY2025 revenue $975M-$979Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $248M | +1% y/y |
| GAAP Net Income · Q3-2025 | $11M | |
| Adjusted EBITDA · Q3-2025 | $58M | |
| Adjusted Diluted EPS · Q3-2025 | $0.87 | |
| GAAP Diluted EPS · Q3-2025 | $0.30 | |
| Operating cash flow · Q3-2025 | $9M | |
| Book-to-bill · Q3-2025 | $1.03 | |
| Bookings growth · Q3-2025 | 17.0% |
Guidance
Q4 revenue $253M-$257M; FY2025 revenue $975M-$979M
Q4 guidance implies return to year-over-year organic growth; FY2026 mid-single digit organic growth expected.
Risks flagged
Operating cash flow declined to $8.5M from $23.0M due to inventory purchases and restructuring.
“Operating cash flow for the third quarter of 2025 was $8.5 million, compared to $23.0 million for the third quarter of 2024.” · word for word
Organic revenue growth negative at -3.8%.
“Organic Revenue Growth... was (3.8)% for the third quarter of 2025”
3 Nov 202510-QNovanta reported Q3 2025 revenue +1.4% YoY (acquisition-driven), operating income -32.9% YoY, and diluted EPS $0.30 vs $0.53. Gross margin improved slightly; SG&A and restructuring costs weighed on profitability.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $248M | +1% y/y |
| Gross profit margin · Q3-2025 | 44.8% | |
| Operating income · Q3-2025 | $22M | -33% y/y |
| Diluted EPS · Q3-2025 | $0.30 | -43% y/y |
| Total revenue · 9M-2025 | $722M | +2% y/y |
| Operating cash flow · 9M-2025 | $55M | -43% y/y |
| Cash and cash equivalents · 2025-09-26 | $89M |
Risks flagged
Tariff and trade policy uncertainty
“Economic tensions and changes in trade policies, such as higher tariffs, retaliatory measures, renegotiated free trade agreements, changes in government funding, and the ongoing impact from prolonged inflationary pressures have impacted the global market for our products and the cost to manufacture.” · word for word
Restructuring execution risk
“We recorded restructuring, acquisition, and related costs of $6.7 million during the three months ended September 26, 2025, versus $2.5 million during the prior year period.” · word for word
ERP implementation disruption
“The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs associated with planning and design phase of our enterprise resource planning (“ERP”) system implementation.” · word for word
Foreign exchange exposure
“Foreign exchange transaction gains (losses) were $(3.1) million for the nine months ended September 26, 2025 and $(0.8) million for the prior year period.” · word for word
Novanta Inc. — questions
- What did Novanta Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — Novanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medical.
Every figure on this page comes from Novanta Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.